Atea Pharmaceuticals second quarter 2026 loss of $0.41 per share beat estimates by $0.15

Atea Pharmaceuticals reported zero revenue for the second quarter of 2026, which is consistent with its status as a clinical-stage biopharmaceutical company. The net loss for the period was $32.9 million, or $0.41 per share, representing a narrower loss than the $37.2 million reported in the prior-year quarter and outperforming analyst expectations for a $0.56 per share loss.

Key Highlights

• The Phase 3 C-BEYOND trial for Hepatitis C (HCV) met its primary endpoint of statistical non-inferiority with a 93.9% sustained virologic response (SVR) rate.
• Cash, cash equivalents, and marketable securities totaled $219.5 million, providing liquidity to support operations through the planned NDA submission in the second quarter of 2027.
• Total operating expenses decreased 15% year-over-year to $35.1 million, primarily due to lower clinical development external spending as the C-BEYOND trial moved past peak patient visits.